Dr. Gabriel A. Brooks discusses what DPD deficiency is and why it is important for patients with cancer receiving 5-FU or ...

The physician's choice of therapy included Novartis' EGFR/HER2 inhibitor Tykerb (lapatinib) plus Roche's chemotherapeutic drug Xeloda (capecitabine), or Roche's HER2 therapy Herceptin (trastuzumab ...

Researchers have found Brukinsa to be a potentially safer alternative for patients with chronic lymphocytic leukemia.

For example, in March 2024, the FDA 2 made labelling changes to injectable 5-fluorouracil (5-FU, capecitabine (Xeloda)) warning clinicians that treatment comes with a strong risk of severe side ...